Dimerix Limited – Recent Trading Activity and Corporate Update
Market Performance
| Metric | Value |
|---|---|
| Current Price (11:27 PM CET, 22 Nov 2026) | AUD 0.20 |
| 24‑hour Change | +2.44 % |
| 24‑hour Volume | AUD 54,800 |
| Shares Outstanding | 600.4 million |
| Market Capitalisation | AUD 126.1 million |
| 12‑month Change | –12.5 % |
| 200‑day Simple Moving Average | AUD 0.31 |
| 52‑Week High | AUD 0.66 (23 Dec 2025) |
| 52‑Week Low | AUD 0.16 (11 Jun 2026) |
The stock closed at AUD 0.20 on Thursday, 22 November 2026, marking a 2.44 % increase from the previous close. In the last 24 hours, the company traded for a total value of AUD 54.8 k against a daily volume of 600.4 million shares. Since the end of the previous month, Dimerix has experienced a 12.5 % decline in its share price.
Upcoming Corporate Actions
- Annual General Meeting (AGM)
- Date: 20 November 2026
- Agenda items:
- Presentation of financial statements for the year ended 30 June 2026.
- Non‑binding resolution to adopt the remuneration report.
- Re‑election of Directors Dr. James Williams and Mr. Paul House.
- Shareholder vote on equity‑based incentives for CEO David Morris, including share‑in‑lieu of short‑term incentive payments, sign‑on rights, and long‑term incentive performance rights.
- Special resolution to increase the company’s placement capacity by 10 %, enabling future equity issuances without further shareholder approval.
These items reflect the company’s focus on governance, executive remuneration, and capital‑raising flexibility.
24‑Hour Performance of Related Stocks
| Stock | 24‑hour Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Vita Life Sciences (VLS.AX) | 0 % | AUD 2.77 | AUD 150.8 million | 14.12 |
| Austral Australia (AR1.AX) | 0 % | AUD 0.06 | AUD 147.2 million | 5.99 |
| Cettire (CTT.AX) | –8.33 % | AUD 0.40 | AUD 146.8 million | – |
| Readytech (RDY.AX) | +4.17 % | AUD 1.22 | AUD 148.3 million | – |
| Alligator Energy (AGE.AX) | +6.45 % | AUD 0.03 | AUD 149.8 million | – |
The table summarizes the 24‑hour price movements, current trading prices, market capitalisations, and price‑to‑earnings ratios for a set of comparable Australian stocks.
Company Overview
Dimerix Limited is an Australian biotechnology company headquartered in Fitzroy, Australia. The company focuses on the development and marketing of drug therapies for patients with chronic kidney disease and conducts related clinical trials. Dimerix serves the Australian market and provides information on its operations through its website at www.dimerix.com and via trading on the ASX All Markets platform.
